Leader Patent-Cliff Exposure & CMS Drug Spending Portfolio

Leader (US): 112 reconciled FDA prescription therapies, $8.6M 2024 CMS Part D & Medicaid spend, and 8 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies112
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE DateMulti-asset schedule
2024 CMS Total Public Spend$8.6M
2024 Medicare Part D Spend$1K
2024 Medicaid Spend$8.6M
California HCAI SB 17 Filings8 WAC filings (max 52.0% 2-yr change)